Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Alone or in Combination for Metastatic Pancreatic Cancer
NCT00012220Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2001
- Primary completion
- Jun 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of gemcitabine in pancreatic cancer (PC) (4 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Overall Survival. Started Jan 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00012220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012220.